FDA Grants Priority Review to Pfizer's COVID-19 Vaccine
- 3 years ago
FDA Grants , Priority Review to, Pfizer's COVID-19 Vaccine.
On July 16, the U.S. Food and Drug Administration (FDA) announced that the Pfizer/BioNTech COVID-19 vaccine has been granted priority review for full approval.
On July 16, the U.S. Food and Drug Administration (FDA) announced that the Pfizer/BioNTech COVID-19 vaccine has been granted priority review for full approval.
The goal is to have a decision
from the FDA by January 2022.
Typically, the priority review process takes
six months, but it could come sooner.
Andy Slavitt, former
White House senior adviser
for COVID-19 response,
said approval could come
as early as July, although
it's a detailed process.
There's a lot of moving pieces. It's not as easy. Hopefully in the next four to five weeks, and I think that will be very, very good news, Andy Slavitt, to CNN's Alisyn Camerota.
Pfizer and BioNTech submitted a
Biologics License Application for their
vaccine for people ages 16 and up in May
On July 16, the U.S. Food and Drug Administration (FDA) announced that the Pfizer/BioNTech COVID-19 vaccine has been granted priority review for full approval.
On July 16, the U.S. Food and Drug Administration (FDA) announced that the Pfizer/BioNTech COVID-19 vaccine has been granted priority review for full approval.
The goal is to have a decision
from the FDA by January 2022.
Typically, the priority review process takes
six months, but it could come sooner.
Andy Slavitt, former
White House senior adviser
for COVID-19 response,
said approval could come
as early as July, although
it's a detailed process.
There's a lot of moving pieces. It's not as easy. Hopefully in the next four to five weeks, and I think that will be very, very good news, Andy Slavitt, to CNN's Alisyn Camerota.
Pfizer and BioNTech submitted a
Biologics License Application for their
vaccine for people ages 16 and up in May